A Phase 1 Study to Investigate the Effect of LY3437943 on the Pharmacokinetics of the Combined Oral Contraceptive Ethinyl Estradiol and Drospirenone in Female Participants
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Retatrutide (Primary) ; Drospirenone; Ethinylestradiol
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 26 Jul 2024 Status changed from active, no longer recruiting to completed.
- 26 Jun 2024 Planned End Date changed from 5 Jul 2024 to 1 Jul 2024.
- 26 Jun 2024 Planned primary completion date changed from 4 Jul 2024 to 1 Jul 2024.